Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > OF THE UTMOST IMPORTANCE

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jan 28, 2021 8:53am

99 Views

Post# 32407622

RE: OF THE UTMOST IMPORTANCE

Ya sure...thats not what they said yesterday .......immune response took longer than expected in several animals .....

Charleyfarley wrote:
VaxilBio is further ahead with the testing of experimental Signal Peptides than is being shared via Newswire. Respecting the process involved and the Timing of communication is of vast importance to all involved. We very well may be in for a surprise in early February. The company has the wind behind them at this time and will adjust the Sails in due time. Be prepared.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks